Spots Global Cancer Trial Database for A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan
Official Title: A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan
Study ID: NCT03165422
Conditions
Interventions
Study Description
Brief Summary: This is a medical chart review of ipilimumab treatment after nivolumab treatment in melanoma in Japan
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution, Minato-ku, Tokyo, Japan
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
